1. ST2 is independently associated with acute GVHD after day 28 after CB transplantation recipients.
Introduction
Unrelated donor cord blood (CB) is routinely used as an alternative hematopoietic stem cell (HSC) source for the transplantation of patients with high-risk hematologic malignancies, and the use of double-unit grafts has greatly extended the application of CB transplantation (CBT) in adults 1, 2 . However, acute graft-versus-host disease (aGVHD) is common with an incidence of grade II-IV aGVHD of at least 50% in double-unit CBT (DCBT) recipients transplanted with calcineurin inhibitor-based prophylaxis and no anti-thymocyte globulin [3] [4] [5] [6] . Moreover, approximately one quarter of patients develop grade III-IV disease, and severe aGVHD is a leading source of morbidity and transplant-related mortality (TRM) after CBT 4, 7 .
Plasma biomarkers have emerged as an important tool in the diagnosis of aGVHD after adult donor hematopoietic stem cell (HSC) transplantation. The biomarkers interleukin2 receptor alpha (IL2Rα), tumor necrosis factor receptor 1 (TNFR1), hepatocyte growth factor (HGF), interleukin-8 (IL8), elafin and regenerating islet-derived protein 3-alpha (Reg3α) are associated with the diagnosis of aGVHD and are significantly associated with the subsequent risk of day 180 TRM in unmodified allograft recipients [8] [9] [10] [11] [12] . Furthermore, levels of the biomarker suppressor of tumorigenicity 2 (ST2) levels obtained at the time of onset of aGVHD are associated with the risk of treatment-resistant aGVHD and 6-month TRM after aGVHD onset independent of aGVHD clinical grade 13 .
Whether GVHD biomarkers are informative in CBT recipients has not been investigated, and such biomarkers could have significant clinical utility. In a previous analysis at Memorial Sloan Kettering
Cancer Center (MSKCC) of 115 recipients of DCBT, we found that the gastrointestinal (GI) tract is the organ most commonly affected in approximately 80% of patients with grade II-IV aGVHD 5 . Similarly, Alsultan et al also found that the gut was the predominant organ affected by aGVHD in CBT recipients 14 .
Accurate diagnosis of GVHD early after transplantation, however, can be complicated by preparative
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Tailoring intensity of aGVHD therapy to the predicted severity of disease prior to clinical manifestations could also be greatly beneficial. Therefore, we investigated the clinical significance of day 28 peripheral blood biomarker levels in DCBT recipients transplanted at MSKCC. Our hypothesis was that elevated day 28 biomarker levels would be associated with the subsequent development of grade III-IV aGVHD.
Methods

Patients and Graft Characteristics
This analysis was performed in patients transplanted at MSKCC between May 1st, 2006 and May 31 st , 2012. All CBT recipients during this time period received double-unit grafts. Patients eligible for this analysis included all consecutive adult and pediatric recipients who achieved donor-derived neutrophil engraftment and had plasma or serum samples obtained at day 28 after DCBT. Of the 113 evaluable patients, 7 developed grade II-IV aGVHD < day 28 post-DCBT. These patients were excluded from aGVHD analyses but were evaluable for the TRM analysis. All patients provided written informed consent for transplantation and research specimen collection, and the analysis was approved by the MSKCC Institutional Review/Privacy Board. Research was conducted in accordance with the Declaration of Helsinki.
CB units were selected according to 4-6/6 HLA-A,-B antigen, -DRB1 allele donor-recipient match, a cryopreserved total nucleated cell (TNC) dose of at least 1.5 x 10 7 / kilogram (kg)/ unit, and the bank of origin 21 . Unit-unit HLA-match was not considered in CB unit selection. High resolution HLA-A,-B,-C,-DRB1,-DQ allele typing of CB units was done routinely but usually did not influence unit selection. Units were thawed using albumin-dextran dilution 22 (n = 219) or thawed with wash (n = 7).
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Conditioning Regimen and GVHD Prophylaxis
All patients were cared for in high-efficiency particulate air filtered rooms and received similar supportive care. Pre-transplant conditioning varied in intensity according to patient's age, diagnosis, remission status, and co-morbidities as previously described 5, 7 . Reduced intensity regimens were functionally myeloablative. All patients received a calcineurin-inhibitor (predominantly cyclosporine-A) and mycophenolate mofetil (MMF) prophylaxis starting on day -3 intravenously as previously described 5, 7 and none received anti-thymocyte globulin (ATG) 5 . Granulocyte-colony-stimulating factor was given post-transplant to promote neutrophil recovery.
Peripheral Blood Samples
All blood samples (either serum or plasma) were prospectively collected at day 28 after DCBT and stored per institutional guidelines at MSKCC. The frozen samples were batch-shipped to the and all others from R&D systems (Minneapolis, MN). Duoset kits were used for TNFR1, IL2Rα, elafin and HGF, and quantikine kits for ST2 as they permit comparable measurements in plasma or serum.
Measurement of ST2 levels by the duoset kit as previously reported by Vander Lugt et al 13 was not selected for this study since they only allow measurement of plasma samples. Samples were analyzed in duplicate as previously described 13 . Laboratory investigators were blinded to all clinical information and transplant outcomes. Pipetting for Reg3α assay (384 well plate format) was performed using Data on patient characteristics and transplant-related outcomes were obtained from the prospectively maintained MSKCC transplant database verified by primary source documentation. The cumulative incidence of aGVHD and TRM were estimated using cumulative incidence functions, with relapse or death in the absence of aGVHD and relapse considered competing risks for aGVHD and TRM, respectively. A landmark analysis was used for each outcome to account for the fact that selected biomarkers were evaluated at day 28 and not at the time of transplant. Patients were grouped according to being above or below the median day 28 value for each biomarker. Biomarkers levels above the median are henceforth described as high whereas levels below the median were considered low. In addition, we generated receiver operating characteristic (ROC) curves to explore other ST2 thresholds as discriminators for grade III-IV aGVHD after day 28 and TRM 26 . The area under the ROC curve (AUC) and true positive and false positive rates at select ST2 thresholds are presented. Gray's test was used to compare the incidence of aGVHD and TRM across biomarker groups. Univariate and multivariate Cox proportional hazard regression models were used to further examine the association between ST2 levels and the cause-specific hazard of aGVHD (after day 28) and TRM (all patients). An interaction term with ST2 and each patient and treatment characteristic was fit in a Cox regression model to explore potential modifiers of the ST2 association with GVHD and TRM. The concordance probability estimate (CPE) was analyzed for each multivariate model before and after the inclusion of the ST2 level to evaluate the marginal increase in predictive accuracy (concordance) after the ST2 level inclusion 27 . HLA-A,-B,-DRB1
allele match of the dominant unit with the patient was used to analyze the association between HLAmatch grade and aGVHD risk after day 28 as this has been shown to have a significant association with aGVHD in a prior analysis at our center 5 . All analyses were performed using R 3.0.3 (R Development
Core Team, 2011, Vienna, Austria).
Results
Patient and Graft Demographics
Patient demographics are summarized in Table 1 . One-hundred and thirteen patients, Overall, 69 of the total 113 patient cohort developed grade II-IV aGVHD prior to day 180 for a day 180 cumulative incidence of 61% (95%CI: 51-69, median onset 40 days, range 17-161). Twentyeight patients had grade III-IV disease (22 grade III, 6 grade IV) for a cumulative incidence of 25% (95%CI: 17-33) by day 180. The GI tract (either upper and/or lower tract) was the organ most commonly affected in 56/69 (81%) of patients, followed by the skin (36/69, 52%), and the liver was the least commonly involved (9/69, 13%). Thirty-four patients had grade II gut aGVHD. Of these, 27 were treated with budesonide as sole treatment, and 23 of these patients responded to therapy with either complete or partial response by day 28 post-treatment. Of the 36 patients affected with skin aGVHD, 18 had stage 1-2, 18 had stage 3, and none had stage 4 disease. The incidence of chronic GVHD at 1 year was 14% (95%CI: 9-21).
The day 180 cumulative incidence of TRM was 14% (95%CI: 9-21). At day 180, 16 patients died of TRM (9 GVHD, 5 organ failure, 2 infection). By 2-years after transplant, the primary transplant-related causes of death included GVHD in 16, organ failure in 6, and infection in 2.
Association Between Day 28 ST2 Levels and Subsequent Acute Graft-versus-Host Disease Risk
In the total group of 113 patients, the median ST2 level was 33.9 ng/ml (IQR 18.3-75.5). This median value was used as the threshold to evaluate differences in patients with high versus low ST2 levels. The association between day 28 ST2 levels and aGVHD with an onset after day 28 was first evaluated in a total of 106 patients (the 7 patients whose aGVHD onset was < day 28 were excluded).
Sixty-two in this 106 patient subset developed grade II-IV aGVHD after day 28 with a median onset of 42.5 days (range 29-161). The cumulative incidence of day 180 grade II-IV aGVHD among patients with high ST2 levels was 66% (95%CI: 51-78) as compared to 52% (95%CI: 38-64) among patients with low
For personal use only. on April 8, 2017 . by guest www.bloodjournal.org From ST2 levels (p = 0.048). Moreover, there was also a significant association between high day 28 ST2 levels and grade III-IV aGVHD when analyzed as above versus below the median ( Figure 1 and Table 2 ). The association between lower GI aGVHD involvement and ST2 levels were evaluated. High ST2 level patients had an incidence of grade II-IV aGVHD involving the lower gut at day 180 of 26% (95%CI: 15-39) whereas the incidence in low ST2 level patients was 16% (95%CI: 8-27) (p = 0.245).
We evaluated the distribution of ST2 levels according to GVHD severity (grade 0-I aGVHD versus II-IV aGVHD). We found that the median ST2 levels were 27.5 ng/ml (IQR 18.7-66.1) and 38.3 ng/ml (IQR 17.5-67.7) in these patient groups, respectively, suggesting that the median value of 33.9 ng/ml for the entire patient cohort is an appropriate threshold for this analysis. The ROC curve for grade III-IV aGVHD was also generated to explore appropriate ST2 thresholds. The corresponding AUC for the ROC curve level was 0.59 (supplemental data, Figure 1A ). The false positive rate associated with the median ST2 level was 0.44 whereas the true positive rate was 0.62.
We evaluated potential risk factors for grade III-IV aGVHD other than the ST2 level in the 106 aGVHD after day 28 patient cohort. We first evaluated the distribution of day 28 ST2 levels according to the conditioning regimen. Of the 106 patient cohort, 80 received myeloablative conditioning and had a median ST2 level of 34.0 ng/ml (IQR 18.5-68.5) whereas the 26 recipients of non-myeloablative conditioning had a median ST2 level of 26.2 ng/ml (IQR 17.1-59.9), p = 0.252. We then performed a univariate analysis to test the association between potential risk factors and day 180 grade III-IV aGVHD (Table 2 ). There was no association with patient age (0-15 versus > 16 years), conditioning regimen intensity (myeloablative versus non-myeloablative), or infused total CD3+ cell dose/kg. The dominant unit-recipient high resolution HLA-A,-B,-DRB1 allele match (2-3/6 versus 4-6/6) showed a trend toward significance (p = 0.077). No patient or treatment characteristic significantly modified the ST2 association with GVHD (data not shown). In a multivariate analysis including day 28 ST2 levels and dominant unit-recipient HLA-allele match, a high day 28 ST2 level was independently associated with an increased risk of subsequent grade III-IV aGVHD [hazard ratio 2.62 (95%CI: 1.06-6.45), p = 0.036] whereas dominant unit-recipient HLAallele match was no longer significant ( Table 3 ). The CPE for HLA-match alone was 0.57, and this increased to 0.65 when ST2 was added.
Association Between Day 28 ST2 Levels and Transplant-Related Mortality
All 113 patients were assessed for the association between ST2 level and day 180 TRM. High day 28 ST2 levels were associated with substantially increased TRM with a cumulative incidence at day 180 post-DCBT of 23% (95%CI: 13-35) as compared to 5% (95%CI: 1-13) in the low ST2 level group, (p = 0.001) ( Table 4 and Figure 2 ). The ROC curve had a corresponding AUC of 0.75. The false positive and true positive rates at the ST2 median value were 0.49 and 0.78, respectively (supplemental data, Figure   1B ). Of the 19/56 patients with high day 28 ST2 levels who died from transplant-related causes, GVHD was the most common cause [12/19 (63%) of deaths] with a median time to GVHD death of 173 days (range 70-465). Of those, aGVHD developed in all patients and 2 had subsequent overlap syndrome (1 mild, 1 severe). Organ failure (exclusively pulmonary) was the second most common cause of death in this group (n = 6) and infection was the least common (n = 1). In contrast, during the period of the study only 5/57 patients with low day 28 ST2 levels died from transplant-related causes. Their primary causes of death were GVHD (n = 4) or infection (n = 1).
Univariate analysis for other risk factors potentially associated with TRM showed that conditioning regimen (myeloablative versus non-myeloablative), dominant unit TNC dose x 10 7 /kg , dominant unit CD34+ cell dose x 10 5 /kg , and dominant unit-recipient high resolution HLA-allele match (2-3/6 versus 4-6/6) were not significant ( Table 5 ). The CPE estimated for the multivariate model without ST2 was 0.68, and this increased to 0.74 with the inclusion of ST2.
Other Biomarkers
The association between other day 28 biomarkers (TNFR1, IL-8, Reg3α, IL2Rα, Elafin and HGF) and transplant outcomes was also analyzed. While biomarker concentrations greater than the median of TNFR1 (> 4792 pg/ml), IL-8 (> 51 pg/ml), and Reg3α (> 42 ng/ml) were not associated with differences in grade II-IV or III-IV aGVHD, they were significantly associated with increased TRM. Similar to high ST2 levels, GVHD was the predominant cause of transplant-related death in patients with high levels followed by pulmonary toxicity. In contrast, biomarker concentrations greater than the median of IL2Rα (> 2426 pg/ml), elafin (> 5155 pg/ml) and HGF (> 940 pg/ml) were not associated with either grade II-IV and III-IV aGVHD or TRM (Table 6 ).
Discussion
CB allografts are routinely transplanted with very high levels of donor-recipient HLAmismatch 5,28,29 and yet the incidence of GVHD after CBT is lower than expected for the degree of HLAmismatch. However, GVHD is a significant complication of CBT and although it can be abrogated by ATG, in vivo T-cell depletion has the disadvantage of the potential abrogation of graft-versus-leukemia effects after reduced intensity allografts 30 and a high risk of opportunistic infections 31-34 . Our center has elected to pursue CBT with an ATG-free platform and while CBT GVHD can be highly corticosteroid responsive, a minority of patients will develop severe or lethal disease 5 . Moreover, we have previously
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ST2 is the receptor of interleukin-33 (IL-33) and is present in two isoforms, a membrane-form expressed on hematopoietic cells especially T helper 2 (Th2) cells, and a soluble form secreted by endothelial cells, epithelial cells, and fibroblasts in response to inflammatory stimuli 35 . Soluble ST2 acts as a decoy receptor for IL-33 limiting its access to Th2 cells and promoting Th1 phenotype which has been associated in aGVHD pathophysiology 36, 37 . In this study, we show for the first time that an elevated ST2 level is independently associated with an increased risk of grade II-IV and III-IV aGVHD in recipients of double-unit CB grafts. It is well established that donor-recipient HLA-match is a critical determinant of CBT outcome including an association with aGVHD and TRM 5, 38, 39 . Nonetheless, not all recipients of highly mismatched CB grafts suffer severe aGVHD, and in this analysis elevated ST2 level for severe aGVHD added predictive value beyond dominant unit-recipient 6 allele HLA-match. This finding is important as although many centers are now appropriately selecting CB units based on high resolution HLA-match, some patients will still receive units with a high degree of mismatch. Therefore, our findings warrant further investigation in a larger cohort to be able to analyze the additional value of ST2 levels, especially in recipients of highly HLA-mismatched grafts.
Importantly, a high day 28 ST2 level was also predictive of increased TRM. Notably, the association with TRM is consistent with that of adult donor allograft recipients 13 . That aGVHD was the predominant cause of death in patients with high day 28 ST2 levels reinforces the potential clinical utility of early detection of elevated levels and early therapeutic intervention especially as aGVHD onset is after day 28 in the majority of patients. However, the optimal time to measure biomarkers is yet to be
For personal use only. on April 8, 2017 . by guest www.bloodjournal.org From determined and in our analysis 7 patients developed GVHD < day 28. Prospective evaluation of serial biomarker measurements from very early post-transplant and at the time of GVHD diagnosis is needed to refine the predictive value of these assays in CBT. In addition, while the median ST2 value had good overall performance relative to other potential thresholds, additional studies should further explore alternatives and elucidate the categorization with the highest clinical utility. Whether ST2 levels, for example, will also provide prognostic information independent of aGVHD grade also requires investigation. In the future, early or pre-emptive interventions based on high biomarker levels could be evaluated. Targeting higher therapeutic calcineurin-inhibitor levels [40] [41] [42] [43] , delaying MMF taper 5 , dosing MMF according to therapeutic trough levels 44, 45 , gut flora manipulation 46 , tailoring the dose of systemic corticosteroids for aGVHD treatment, or treating with IL-22 47 are all possible strategies.
We found that the ST2 values in this analysis were different from that reported by Vander Lugt et al 13 . The likely explanation for this is the use of the more reliable ST2 quantikine kit in this analysis. This emphasizes the need to strictly standardize ST2 testing methodology in future studies. It is also possible that the clinically relevant threshold for this biomarker could differ among HSC sources. Therefore, algorithms to assign specific thresholds for intervention by HSC source will need to be established, ideally by prospective multicenter trials. Additionally, patients with high day 28 ST2 levels who died of organ toxicity had exclusively lung involvement. It would be beneficial to understand the mechanism of the association between ST2 elevation and pulmonary toxicity. One possible explanation is that the pulmonary toxicity is due to idiopathic pneumonia syndrome (IPS). This has been considered an aGVHD equivalent in the lungs by some investigators 48 . This association is supported by data from the Paczesny Laboratory (unpublished, 2014) who have found increased ST2 levels in patients with IPS, and the pathophysiology of this observation requires investigation.
Whether the other biomarkers (TNFR1, IL-8, REG3α, IL2Rα, elafin and HGF) evaluated in this study have additional prognostic importance is unclear. A significant negative finding in this study was
For personal use only. on April 8, 2017 . by guest www.bloodjournal.org From the lack of an association between elafin levels and aGVHD. This could be due to very few patients having stage 3 skin aGVHD and none having stage 4 disease. The corticosteroid responsiveness of skin aGVHD that has been observed in nearly all CBT recipients in our center may also be relevant. However, analysis in a larger population is needed to further investigate this question. It is notable that while elevated levels of TNFR1, IL-8, and Reg3α were not associated with the incidence of grade II-IV and III-IV aGVHD, they were associated with aGVHD lethality. Thus, elevation of these biomarkers could further support the identification of a patient at significant TRM risk and further prospective evaluation addressing this question is indicated. It would be important to establish whether measurement of biomarkers earlier after CBT is also predictive of severe aGVHD and TRM given earlier intervention may be more effective than at 4 weeks post-transplantation. Additionally, understanding the role of ST2 levels in predicting treatment response or the subsequent evolution to overlap syndrome or development of chronic classic GVHD is required. The ultimate aim of these studies is to ameliorate severe GVHD and further improve survival in CBT recipients. DCBT recipients with elevated day 28 ST2 had a significantly increased risk of TRM.
